EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape

EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe’s complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organisation champions biotechs developing rare-disease therapies, advanced cell and gene treatments, and other high-risk innovations that frequently begin with narrow pipelines before scaling or partnering with larger firms. Europe’s scientific strengths are increasingly tested by U.S. pricing pressures, slower market entry, and heavier administrative loads that threaten future investment.

SME Pressures Under the Pharma Package

The revised EU General Pharmaceutical Legislation offers regulatory sandboxes and platform evaluations that could suit personalised medicines and ultra-rare indications. Yet cuts to orphan exclusivity and the introduction of a Global Orphan Marketing Authorisation tied to the active substance raise doubts about commercial returns for incremental advances. These changes risk discouraging smaller developers who already operate with limited capital.

HTA and Trials Execution Gaps

Joint Clinical Assessments under the EU HTA Regulation began in January 2025 for oncology and advanced therapies, aiming for one clinical review across Member States. Early talks with the HTA Coordination Group have been positive, but capacity shortfalls and multiple PICO requests threaten fragmentation. Meanwhile, the Clinical Trials Information System has yet to deliver the expected speed for multinational studies.

Investment Climate for Rare-Disease Biotech

These EUCOPE pharmaceutical regulation developments directly affect HEOR planning, launch sequencing, and reimbursement talks, especially as U.S. reference-pricing proposals link European prices to American revenues. Europe still benefits from world-class centres and regulatory know-how, but sustained competitiveness will depend on pragmatic rollout of reforms and greater predictability in pricing and access rules.